Cited by 286Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record.

A resurrection of aducanumab for Alzheimer's disease

Open access

Schneider, Lon·2020·The Lancet Neurology

DOI 10.1016/s1474-4422(19)30480-6

Open this paper in CoChat — free account Open PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(19)30480-6

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorted by citations

Items 101–200 of 224

Brain Targeting Nanomedicines: Pitfalls and Promise
Käkinen, A., Jiang, Y., Davis, T. P., Teesalu, T., & Saarma, M. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s454553 · Cited by 26
“For example, the US Food and Drug Administration recently approved human monoclonal antibodies aducanumab 98 and lecanemab 99 which target various forms of aggregated Aβ.”
Background
Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20
Neuromodulation in the Treatment of Alzheimer’s Disease: Current and Emerging Approaches
Pople, C. B., Meng, Y., Li, D. Z., Bigioni, L., Davidson, B., Vecchio, L. M., Hamani, C., Rabin, J. S., & Lipsman, N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200913 · Cited by 30
“…strategies such as monoclonal antibodies or active immunization targeting A (cid:2) and to a lesser extent tau are in active clinical trials, though results have been mixed on pathology-related endpoints and largely negative on clinical scores [18, 19], with some recent exceptions [20, 21].”
Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial
Khalifa, K. N., Bergland, A. K., Soennesyn, H., Oppedal, K., Oesterhus, R., Dalen, I., Larsen, A. I., Fladby, T., Brooker, H. J., Wesnes, K. A., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00916 · Cited by 22
“There are no disease-modifying treatments available, and several phase III trials with anti-amyloid agents have failed (6) with some mixed but slightly more promising results with phase-III aducanumab recently reported (7, 8).”
Background
Microglia networks within the tapestry of alzheimer’s disease through spatial transcriptomics
Zhou, Y. F., & Glass, C. K. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00897-y · Cited by 21
“A central question in AD research is how amyloid plaques relate to the neurodegenerative process [65–67].”
Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer’s Disease?1
Kuhn, A. J., & Raskatov, J. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191201 · Cited by 31
“To date, most treatments aimed to cure AD have failed Phase III clinical trials [9], aside from Biogen’s recent revisited analysis of the anti-amyloid antibody drug, aducanumab, which is currently seeking FDA approval [11].”
Innovations in noninvasive sensory stimulation treatments to combat Alzheimer’s disease
Park, J. M., & Tsai, L. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003046 · Cited by 19
“Treatments recently approved by the US Food and Drug Administration, such as aducanumab [7,8] and lecanemab [9], have sparked debate due to their high costs, modest efficacy, and potential side effects.”
The Immune System as a Therapeutic Target for Alzheimer’s Disease
Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 19
Medha Plus – A novel polyherbal formulation ameliorates cognitive behaviors and disease pathology in models of Alzheimer’s disease
Paidi, R. K., Sarkar, S., Ambareen, N., & Biswas, S. C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113086 · Cited by 25
A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimer’s Disease
Mitra, S., Gera, R., Linderoth, B., Lind, G., Wahlberg, L. U., Almqvist, P. M., Behbahani, H., & Eriksdotter, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-74046-7_11 · Cited by 27
Network pharmacology and in vivo studies reveal the neuroprotective effects of paeoniflorin on Alzheimer's disease
Zhang, M., Zheng, H., He, J., & Zhang, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21800 · Cited by 13
“Currently, the drugs used to treat AD are mainly single-target drugs that only delay the symptoms of AD to a certain extent and have a number of side effects [27,28].”
Background
Lung adenocarcinoma-related target gene prediction and drug repositioning
Huang, R., Siriwanna, D., Cho, W. C. S., Wan, T. K., Du, Y. R., Bennett, A. N., He, Q., Liu, J., Huang, X. T., & Chan, K. H. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.936758 · Cited by 18
“…selective serotonin reuptake inhibitors, being potentially suitable for treating lung cancer is not an independent event, as aducanumab, a drug for Alzheimer ’ s disease (Schneider, 2020), has also been experimentally tested for lung cancer and encouraging results were observed (Morrison, 2016).”
Result
Experimental modelling of Alzheimer's disease for therapeutic screening
Blaikie, L., Kay, G., Maciel, P., & Lin, P. K. T. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100044 · Cited by 16
An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
Boopathi, S., Poma, A. B., & Garduño‐Juárez, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910798 · Cited by 20
Infrared Laser-Induced Amyloid Fibril Dissociation: A Joint Experimental/Theoretical Study on the GNNQQNY Peptide
Kawasaki, T., Man, V. H., Sugimoto, Y., Sugiyama, N., Yamamoto, H., Tsukiyama∥, K., Wang, J., Derreumaux, P., & Nguyen, P. H. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c05385 · Cited by 24
Massively parallel genetic perturbation suggests the energetic structure of an amyloid-β transition state
Arutyunyan, A., Seuma, M., Faure, A. J., Bolognesi, B., & Lehner, B. (2025) · Science Advances · doi:10.1126/sciadv.adv1422 · Cited by 21
A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression
Pilozzi, A. R., Foster, S. L., Mischoulon, D., D, M. F. M., & Huang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512513 · Cited by 15
“Aducanumab is presently the only FDA-approved treatment for the causes of AD, targeting Aβ amyloid [7].”
Background
The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer’s disease
Zhao, X., Li, X., She, L., Li, L., Huang, P. C., & Liang, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113188 · Cited by 15
Reparative Effects of Stem Cell Factor and Granulocyte Colony-Stimulating Factor in Aged APP/PS1 Mice
Guo, X., Liu, Y., Morgan, D., & Zhao, L. (2020) · Aging and Disease · doi:10.14336/ad.2020.0201 · Cited by 16
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
Jeong, J., Han, M., Jeon, S., Kim, Y., Choi, H. J., Choi, W., Kwon, K., Choi, J.-R., & Lee, E.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02412-1 · Cited by 13
Comparing Transcranial Direct Current Stimulation (tDCS) with Other Non-Invasive Brain Stimulation (NIBS) in the Treatment of Alzheimer’s Disease: A Literature Review
Wang, C. S., Chang, W. H., Yang, Y. K., & Cheng, K. (2023) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-023-00810-2 · Cited by 18
“However, there is no persuasive evidence to support the approval of aducanumab as the validity from the studies is uncertain [10, 11].”
Background
Anti-dementia drugs: a descriptive study of the prescription pattern in Italy
Ippoliti, I., Ancidoni, A., Cas, R. D., Pierantozzi, A., Vanacore, N., & Trotta, F. (2023) · Neurological Sciences · doi:10.1007/s10072-022-06586-8 · Cited by 18
“In recent years, international attention has been turning toward therapies that modify the natural history of AD [15, 16].”
Background
The Blood-Brain Barrier in Alzheimer’s Disease
Storck, S. E., Hartz, A. M. S., & Pietrzik, C. U. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_418 · Cited by 31
Changes in the brain transcriptome after DNA Aβ42 trimer immunization in a 3xTg-AD mouse model
Lambracht‐Washington, D., Fu, M., Hynan, L. S., & Rosenberg, R. N. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105221 · Cited by 27
“Variations in the outcome of passive immunization in clinical trials can be attributed to the different antibody clones (Gallardo and Holtzman, 2017, Schneider, 2020), as well as to differences comparing active immunization regimen, which we have done by comparing active DNA Aβ42 immunization to…”
Background
CCCDTD5: Reducing the risk of later‐life dementia. Evidence informing the Fifth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD‐5)
Rockwood, K. J., Andrew, M. K., Aubertin‐Leheudre, M., Belleville, S., Bherer, L., Bowles, S. K., Kehler, D. S., Lim, A. S. P., Middleton, L. E., Phillips, N. A., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12083 · Cited by 17
Multidirectional in vitro and in cellulo studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer’s disease
Szałaj, N., Godyń, J., Jończyk, J., Pasieka, A., Panek, D., Wichur, T., Więckowski, K., Zaręba, P., Bajda, M., Pišlar, A. H., et al. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1835882 · Cited by 17
Perinatal Tissue-Derived Stem Cells: An Emerging Therapeutic Strategy for Challenging Neurodegenerative Diseases
Bruno, A., Milillo, C., Anaclerio, F., Buccolini, C., Dell’Elice, A., Angilletta, I., Gatta, M., Ballerini, P., & Antonucci, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020976 · Cited by 16
“Adu-canumab is a human IgG monoclonal antibody targeting A β fibrils and soluble oligomers aimed at clearing the A β plaques and contributing to slow AD development [43,44].”
Background
The neuroprotective effects of Liuwei Dihuang medicine in the APP/PS1 mouse model are dependent on the PI3K/Akt signaling pathway
Yuan, Y., Liu, Y., Li, H., Ma, J., Shao, S., Yu, Z., Shi, M. M., Zhang, Z., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1188893 · Cited by 15
“Although Aduhelm was approved by the FDA in 2021, the drug company provided less information about its clinical trials (Knopman et al., 2019; Schneider, 2019).”
Method
Circulating Exosomes from Alzheimer’s Disease Suppress Vascular Endothelial-Cadherin Expression and Induce Barrier Dysfunction in Recipient Brain Microvascular Endothelial Cell
Bei, J., Miranda-Morales, E. G., Gan, Q., Qiu, Y., Husseinzadeh, S., Liew, J. Y., Chang, Q., Krishnan, B., Gaitas, A., Yuan, S., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230347 · Cited by 18
Dynamic distribution of gut microbiota during Alzheimer's disease progression in a mice model
Zhu, J., Liu, S., Zhang, H., Zhao, W., Ding, J., Dai, R., Xu, K., He, C., Liu, J., Yang, L., et al. (2023) · Apmis · doi:10.1111/apm.13339 · Cited by 14
“It is reported that aducanumab, a human monoclonal antibody, could enter the brain and reduce Ab [32, 33].”
Background
Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity
Rogdakis, T., Charou, D., Latorrata, A., Papadimitriou, E., Tsengenes, A., Athanasiou, C., Papadopoulou, M. A., Chalikiopoulou, C., Κάτσιλα, Θ., Ramos, I., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030614 · Cited by 15
Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
Zampar, S., & Wirths, O. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch2 · Cited by 18
Advanced brain imaging for the diagnosis of Alzheimer disease
Wang, Y.-T. T., Rosa‐Neto, P., & Gauthier, S. G. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001198 · Cited by 16
An Overview of Data Integration in Neuroscience With Focus on Alzheimer's Disease
Turrisi, R., Squillario, M., Abate, G., Uberti, D. L., & Barla, A. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3268729 · Cited by 18
“Although a great effort has been made to identify potential druggable targets, only recently, after a timespan of 20 years, the Food and Drug Administration (FDA) has approved a new drug (Ad-ucanumab) whose true efﬁcacy in modifying the progression of AD is yet to be conﬁrmed [57], [58].”
Background
The Strategies for Treating “Alzheimer’s Disease”: Insulin Signaling May Be a Feasible Target
You, G., Yao, J., Liu, Q., & Li, N. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44120421 · Cited by 12
“To improve the acceleration of Aβ, the monoclonal antibody of Aβ oligomers, such as aducanumab, has been clinically used [29].”
Method
B Lymphocytes in Alzheimer’s Disease—A Comprehensive Review
Plantone, D., Pardini, M., Locci, S., Nobili, F. M., & Stefano, N. D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220261 · Cited by 19
“After an early termination of the trials in March 2019, due to planned futility analysis indicating little chance of treatment efﬁcacy, a more comprehensive reanalysis of the dataset from both studies was presented in 2020 by Biogen that led to a temporary approval by FDA [193, 195].”
Genetic Therapies for Alzheimer’s Disease: A Scoping Review
Lennon, M. J., Rigney, G., Raymont, V., & Sachdev, P. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215145 · Cited by 23
“The recent approval of adu-canumab by the Federal Drug Administration (FDA) has kept the hope of the potential beneﬁt of this strategy alive, although convincing clinical beneﬁt of aducanumab remains to be demonstrated [13, 14].”
The Progress of Label-Free Optical Imaging in Alzheimer’s Disease Screening and Diagnosis
Liu, K., Li, J., Raghunathan, R., Zhao, H., Li, X., & Wong, S. T. C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.699024 · Cited by 12
“Aducanumab was proven to slow down the AD process in the clinical trial and under FDA’s review, but only for MCI and early AD patients (Schneider, 2020; No authors listed, 2021).”
Method
Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease
Waragai, M., Ho, G. J., Takamatsu, Y., Wada, R., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200416 · Cited by 10
“An exception, aducanumab, resulting from a collaborative effort between Eisai and Biogen, although controversial, is still under consideration by the US Food and Drug Administration for potential approval [7].”
Background
Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer’s Disease Patients and In Silico Prediction of Potential Repurposable Drugs
Fagone, P., Mangano, K., Martino, G., Quattropani, M. C. A., Pennisi, M., Bella, R., Fisicaro, F., Nicoletti, F., & Petralia, M. C. (2022) · Genes · doi:10.3390/genes13040703 · Cited by 6
“The analysis was performed using the meta-signatures of FDAapproved compounds only.”
Background
Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer’s Disease
Götz, J., Richter-Stretton, G. L., & Cruz, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071002 · Cited by 15
“One of the two phase III trials of aducanumab, EMERGE, unlike ENGAGE, showed reductions in cognitive decline, possibly reflecting the effects of higher accumulated doses of the antibody [27].”
Mitochondria‐associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease
Wang, K., & Zhang, W. (2021) · Synapse · doi:10.1002/syn.22196 · Cited by 11
“The objections to this conclusion mainly concentrate on the reliability of post hoc analyses, the comparability between high- dose group and placebo group (Schneider, 2020), as well as the overall organization of two studies.”
Background
Private payer coverage policies for ApoE-e4 genetic testing
Arias, J. J., Tyler, A. M., Douglas, M. P., & Phillips, K. A. (2021) · Genetics in Medicine · doi:10.1038/s41436-020-01042-4 · Cited by 11
Targeting Amyloid-β Proteins as Potential Alzheimer’s Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health
Abduljawad, A. A., Alkinani, K. B., Zaakan, A., AlGhamdi, A. S., Hamdoon, A. A. E., Alshanbari, B. H., Alshehri, A. A., Alluhaybi, B. B., Alqashi, S. O. I., & Abduljawad, R. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111731 · Cited by 7
“The manufacturer stated that the discontinuation of the product is not due to safety or efficacy issues but to reprioritize its resources towards lecanemab and the development of other new products [59].”
Cognitive Effect of Transcranial Direct Current Stimulation on Left Dorsolateral Prefrontal Cortex in Mild Alzheimer’s Disease: A Randomized, Double-Blind, Cross-Over Small-Scale Exploratory Study
Wang, C. S., Chen, P. S., Tsai, T.-Y., Hou, N.-T., Tang, C.-H., Chen, P., Huang, Y., & Cheng, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240002 · Cited by 9
An immunological puzzle: The adaptive immune system fuels Alzheimer’s disease pathology
Hoecke, L. V., Castelein, J., Xie, J., Acker, L. V., Imschoot, G. V., Wonterghem, E. V., Vlaeminck, I., Verhaege, D., Claeys, W., Wierda, K. D. B., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.12.026 · Cited by 13
Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease
Xu, Y., Jiang, H., Zhu, B., Cao, M., Feng, T., Sun, Z., Du, G., & Zhao, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14238 · Cited by 11
Efficacy and safety of blood derivatives therapy in Alzheimer’s disease: a systematic review and meta-analysis
Fei, Z., Pan, B., Pei, R., Chen, Z., Du, X., Cao, H., & Li, C. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02115-y · Cited by 9
“Since the amyloid cascade hypothesis was published in 1991, AD therapy has focused primarily on monoclonal anti-Aβ antibodies [62], β-secretase inhibitors [63], and γ-secretase modulators [64] and inhibitors [65].”
Background
How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
Lythgoe, M., & Prasad, V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.012 · Cited by 8
“Two years ago, Biogen halted all clinical development of aducanumab, after an interim analysis of two phase III trials (ENGAGE and EMERGE trials), suggested both were unlikely to show cognitive benefit [2].”
Background
Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics
Thorlacius-Ussing, G., Bruun, M., Gjerum, L., Frederiksen, K. S., Rhodius‐Meester, H. F. M., van der Flier, W. M., Waldemar, G., & Hasselbalch, S. G. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210278 · Cited by 9
“Furthermore, as new treatment options, for especially AD, are expected to emerge in the future, an early accurate etiologic diagnosis becomes increasingly important [35].”
Background
Amyloid Structural Changes Studied by Infrared Microspectroscopy in Bigenic Cellular Models of Alzheimer’s Disease
Paulus, A., Engdahl, A., Yang, Y., Boza‐Serrano, A., Bachiller, S., Torres-Garcia, L., Svanbergsson, A., Garcia, M. G., Gouras, G. K., Li, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073430 · Cited by 11
“been encouraging [13], indicates that the mechanisms of Aβ neurotoxicity are more complex than previously thought [14], and further research is needed to understand the specific role of Aβ and its various molecular species in the pathogenesis of AD.”
Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model
Araya, P., Niemeyer, B., Schade, K., Dunn, L. N., Waugh, K., Busquet, N., Brindley, C., Brown, C., Winkler, C., Lyford, H. R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113130 · Cited by 7
“66 Here, we defined two regions: (1) A β plaque-positive and (2) non-plaque regions adjacent to A β plaques of brains from 5xFAD and 5xFAD-Dp16 mice.”
Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 13
Structural covariance changes in major cortico-basal ganglia and thalamic networks in amyloid-positive patients with white matter hyperintensities
Son, S. J., Hong, C. H., Kim, N., Choi, J. W., Roh, H. W., Lee, H., Seo, S. W., Choi, S. H., Kim, E., Kim, B. C., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.05.010 · Cited by 8
“, 2017) for the disappointing outcomes of disease modifying AD trials (Doody et al., 2014; Hardy and De Strooper, 2017; Schneider, 2020).”
Background
China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study
Zhu, Y., Pan, D., He, L., Rong, X., Li, H., Li, Y., Pi, Y., Xu, Y., & Tang, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.797704 · Cited by 6
“…(FAD) has approved the first AD-treatment drug, aducanumab, which can delay the progression of AD by clearing the amyloid-β (Aβ), (Sevigny et al., 2016; Schneider, 2020) the earliest pathological signature of AD in the brain (Hardy and Selkoe, 2002; Masters et al., 2015; Jack et al., 2018).”
Background
Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis
Zhang, W., Xu, S., Yu, H., Li, X., Jin, Z., Li, Y., & He, Z. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01566-4 · Cited by 8
Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer’s Disease
Bergland, A. K., Proitsi, P., Kirsebom, B., Soennesyn, H., Hye, A., Larsen, A. I., Xu, J., Legido‐Quigley, C., Rajendran, L., Fladby, T., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200441 · Cited by 6
“Despite current clinical trials focusing on altering amyloid metabolism [3], and reports of some positive results [4], no effective disease-modifying treatment is currently available [5].”
Cognitive go/No-go decision-making criteria in Alzheimer’s disease drug development
Wessels, A. M., Edgar, C. J., Nathan, P. J., Siemers, E. R., Maruff, P., & Harrison, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.012 · Cited by 7
A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system
Huang, J., Long, X., & Chen, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1522058 · Cited by 6
“A particularly noteworthy ﬁ nding is the sex-neutral distribution of adverse events, suggesting that aducanumab ’ s safety pro ﬁ le remains consistent across sex (Schneider, 2020; Choi et al., 2023).”
Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer’s disease
Zhang, Y., Yu, W., Zhang, L., & Li, P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2396911 · Cited by 6
“Nevertheless, a new randomized controlled trial is necessary to validate the clinical efficacy of aducanumab [21].”
N,N-dimethylacetamide targets neuroinflammation in Alzheimer’s disease in in-vitro and ex-vivo models
Wei, Z.-H., Koya, J., Acharekar, N., Trejos, J., Dong, X.-D., Schanne, F. A. X., Ashby, C. R., & Reznik, S. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-34355-w · Cited by 7
Emerging concepts towards a translational framework in Alzheimer’s disease
Cozachenco, D., Zimmer, E. R., & Lourenco, M. V. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105246 · Cited by 7
Interactive Effects of Pulse Pressure and Tau Imaging on Longitudinal Cognition
Weigand, A. J., Initiative, A. D. N., Macomber, A. J., Walker, K. S., Edwards, L., Thomas, K. R., Bangen, K. J., Nation, D. A., & Bondi, M. W. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220026 · Cited by 7
“…the questionable efﬁcacy of adu-canumab in ameliorating cognitive decline despite its successful targeting and reductions of A (cid:2) [1, 4, 5], coupled with other negative anti-A (cid:2) clinical trials [6] and research demonstrating little to no association between A (cid:2) burden and…”
A pragmatic trial testing a tailored non pharmacologic therapies on nocturnal behavioral and psychological symptoms associated with dementia
Bautrant, T., Franqui, C., Clément, H., Rabault, M., Masseboeuf, F., Pastore, M., Pardo, M., Brandi, Y., Drouin, N., Brice, A.-D., et al. (2021) · Geriatric Nursing · doi:10.1016/j.gerinurse.2021.11.002 · Cited by 6
Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle
Bartfai, T., & Lees, G. V. (2020) · ASN NEURO · doi:10.1177/1759091420918557 · Cited by 9
“But, randomized data from both trials showed an improvement (Schneider, 2020).”
Background
The Science and Business of Drug Discovery: Demystifying the Jargon
Zanders, E. (2020) · doi:10.1007/978-3-030-57814-5 · Cited by 6
Alzheimer's disease diagnosis and treatment: From pathophysiological insights to therapeutic advances in the era of precision neurology (2025 review)
Kim, M., Kwon, H., Sohn, S., Lee, W. J., Cho, K., & Kim, G. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251391820 · Cited by 12
“9,10 This failure provided critical lessons and led to development of second-generation anti-A β monoclonal antibodies (MABs), 9,10 such as aducanumab, 11 lecanemab, 12 and donanemab.”
A computational framework for identifying chemical compounds to bind Apolipoprotein E4 for Alzheimer’s disease intervention
Zhai, T., Krass, E., Zhang, F., & Huang, Z. J. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1188430 · Cited by 6
“Only seven drugs have been approved by the FDA to treat Alzheimer ’ s disease, including Lecanemab (Swanson, 2021), Aducanumab (Schneider, 2020), Donepezil (Birks et al., 2000), Rivastigmine (Desai and Grossberg, 2005), Memantine (Reisberg et al., 2003), Manufactured combination of memantine and donepezil (Howard, 201…”
BackgroundInfluential
Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT
Kehoe, P. G., Turner, N. L., Howden, B., Jarutyt, L., Clegg, S., Malone, I. B., Barnes, J., Nielsen, C. F., Sudre, C. H., Wilson, A., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08190 · Cited by 7
Exploring the Genetic Associations Between the Use of Statins and Alzheimer's Disease
Lee, J., Park, S., Kim, Y., Kim, H. M., & Oh, C. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.2.133 · Cited by 6
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy
Levites, Y., Funk, C. C., Wang, X., Chakrabarty, P., McFarland, K. N., Bramblett, B., O’Neal, V., Liu, X., Ladd, T. B., Robinson, M., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00453-4 · Cited by 6
“These reanalyzed data, whose interpretation is controversial [20, 21], support a new biologic drug application that is currently being reviewed by the FDA.”
Background
Regulation of autophagy‐mediated pathways by diet, physical activity, and sleep in Alzheimer's disease
Ariyath, A., Mputhia, Z., Dougherty, C., Rahuman, B. K., Fernando, W. M. A. D. B., Brown, B. M., Gardener, S. L., Rainey‐Smith, S. R., Martins, R. N., & Bharadwaj, P. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71191 · Cited by 4
“103,104 116–119”
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias
Perlett, L., & Smith, E. E. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.008 · Cited by 5
In Vivo Dynamic Movement of Polymerized Amyloid β in the Perivascular Space of the Cerebral Cortex in Mice
Hasegawa, I., Hirayoshi, Y., Minatani, S., Mino, T., Takeda, A., & Itoh, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126422 · Cited by 4
“Until now, inhibition of Aβ production by γ-secretase inhibitors was unsuccessful [14], whereas therapies utilizing antibodies to Aβ have been only partially successful [15].”
Background
Investigating Neurophysiological Markers of Symptom Severity in Alzheimer’s Disease
Hoy, K. E., Emonson, M., Bailey, N. W., Humble, G., Coyle, H. L., Rogers, C., & Fitzgerald, P. B. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210401 · Cited by 4
“While some of these drugs showed reductions in amyloid plaque burden (e.g., aducanumab, gantenerumab), this was not associated withclinicalimprovement,castingdoubtonthevalid-ityofsolelytargetingamyloid[4–6].”
Nové pohledy na léčbu demence
Bajtošová, R., Holmerová, I., & Rusina, R. (2021) · Neurologie pro praxi · doi:10.36290/neu.2021.014 · Cited by 4
Novel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein
Xie, Y., Wang, Y., Jiang, S., Xiang, X., Wang, J., & Ning, L. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1973482 · Cited by 6
“Decreased plaques in cortical brain regions were found in patients with mild Alzheimer’s disease, who had received Aducanumab treatment for 12months [106].”
Background
A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation
Prins, S., Zhuparris, A., Hart, E. P., Doll, R. J., & Groeneveld, G. J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00874-9 · Cited by 8
“Further analyses showed that in one of the two phase 3 trials the patient group that received the highest dose of the active compound showed slower cognitive decline than the placebo group [5].”
Background
Aducanumab for Alzheimer's disease: An update
Retinasamy, T., & Shaikh, M. F. (2021) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v4i2.81 · Cited by 5
“In December 2018, both the studies went through a futility analysis; a test used to evaluate if the trial is worth continuing to completion based on preliminary data (Schneider, 2020).”
BackgroundMethodInfluential
Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases
Bowerman, M. (2020) · Brain Sciences · doi:10.3390/brainsci10090633 · Cited by 6
Correlating retinal and choroidal vascular parameters with volumetric MRI in Alzheimer’s disease and amnestic mild cognitive impairment
Zhao, W., Robbins, C. B., Grewal, D. S., Patel, H. H., Soundararajan, S., Liu, A., Johnson, K. G., Agrawal, R. V., Petrella, J. R., Stinnett, S. S., et al. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-04157-x · Cited by 4
Alzheimer’s disease: an integrative bioinformatics and machine learning analysis reveals glutamine metabolism-associated gene biomarkers
Xing, N.-F., Yan, J., Gao, R.-H., Zhang, A.-H., He, H.-Y., Zheng, M., & Li, G.-J. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00852-z · Cited by 3
“This progression culminates in a profound degradation of life quality for patients [23].”
Beyond genetics: including the environmental dimension in amyloidosis mouse models for Alzheimer’s disease
Hoecke, L. V., & Vandenbroucke, R. E. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01747-6 · Cited by 2
“While recent FDA approvals for Aducanumab and Lecanemab have generated optimism, these therapies offer only partial relief by slowing cognitive decline [1–2], leaving us ill-equipped to face the looming AD epidemic.”
Background
Circulating exosomes from Alzheimer’s disease suppress VE-cadherin expression and induce barrier dysfunction in recipient brain microvascular endothelial cellPreprint
Bei, J., Miranda-Morales, E. G., Gan, Q., Qiu, Y., Husseinzadeh, S., Liew, J. Y., Chang, Q., Krishnan, B., Gaitas, A., Yuan, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.03.535441 · Cited by 3
Effect of a multi-domain intervention on the quality of life in older adults with major neurocognitive disorder: A pilot study
Koskas, P., Kohler, S., Estrada, J., Sebbagh, M., Lacaille, S., & Lilamand, M. (2021) · Revue Neurologique · doi:10.1016/j.neurol.2021.06.010 · Cited by 3
Pharmacological drug strategies in Alzheimer's Disease
Dantas, R. L. M., Baracho, N. C., Camins, A., & Ettcheto, M. (2021) · Revista Neurociências · doi:10.34024/rnc.2021.v29.12413 · Cited by 2
The promise of artificial neural networks, EEG, and MRI for Alzheimer’s disease
Bailey, N. W., & Hoy, K. E. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.10.009 · Cited by 3
A pragmatic tool to identify aspects of frailty
Russ, T. C., & Welstead, M. (2020) · International Psychogeriatrics · doi:10.1017/s1041610220000204 · Cited by 3
“Numerous trials of disease-modifying treatments are ongoing and, while many people remain optimistic, with perhaps one exception there have been no major successes in past decades (Schneider, 2019).”
Background
Alzheimer’s Disease Pharmacology
Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 6
‘The awesome power of yeast’ in Alzheimer’s disease research
Dhakal, S. (2021) · Microbiology Australia · doi:10.1071/ma21034 · Cited by 3
Mechanistic Population Pharmacokinetic–Pharmacodynamic Model of the Tau‐Targeted Antibody Posdinemab in Healthy Participants and Participants with Alzheimer’s Disease
Pérez‐Ruixo, C., Li, L., Galpern, W. R., & Ruixo, J. J. P. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70173 · Cited by 2
“5,6 Anti-amyloid monoclonal antibodies—lecanemab, donanemab, and aducanumab—have reduced amyloid burden and slowed cognitive decline in AD, 7–9 leading to approval by the U.S. Food and Drug Administration.”
Cordia dichotoma G. Forst fruit prophylactic against Alzheimer's risk factors: in vitro study
Ibrahim, F. M., Ibrahim, A. Y., Amer, H. M., Ramadan, M. F., & Mohammed, R. S. (2024) · RENDICONTI LINCEI · doi:10.1007/s12210-024-01283-4 · Cited by 2
“…previous hypothesis, four main types of FDA-approved anti-AD drugs: acetylcholinesterase inhibitors (Agrawal et al. 2018; Zhang and Gordon 2018), NMDA receptor antagonists (Lu and Nasrallah 2018 ), Aβ inhibitors (Sevigny et al. 2016; Schneider 2020 ) and intestinal flora regulators (GV-971, 2019).”
CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer’s Disease Treatment: A Systematic Review of Available Clinical Data
Thitilertdecha, P., & Brimson, J. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230994 · Cited by 3
“However, studies of its effects on cognitive decline in AD have been less clear-cut, with only three of 16 dementia rating scales being nominally signiﬁcant at a p = 0.05 threshold at 12 months [54].”
Influential
Monomeric Amyloid Peptide-induced Toxicity in Human Oligodendrocyte Cell Line and Mouse Brain Primary Mixed-glial Cell Cultures: Evidence for a Neuroprotective Effect of Neurosteroid 3α-O-allyl-allopregnanolone
Okechukwu, N. G., Klein, C., Jamann, H., Maître, M., Patte‐Mensah, C., & Mensah‐Nyagan, A. G. (2024) · Neurotoxicity Research · doi:10.1007/s12640-024-00715-1 · Cited by 2
“…nM to 1 µM) extremely lower than 3 µM, which exhibited also a very low AI (-2.0) confirming their Aβ monomeric state (Gupta and Mahalakshmi 2019, 2020; Herrera et al. 2016; Pignataro et al. 2020; Shen and Murphy 1995), significantly decreased the viability of the HOG cell line and mouse brain…”
Influential
Gold nanoparticles with amyloid-β reduce neurocell cytotoxicity for the treatment and care of Alzheimer’s disease therapy
Hong, Q., Jin, X., Zhou, C., & Shao, J. (2023) · Gold bulletin · doi:10.1007/s13404-023-00327-1 · Cited by 3
“4% of medication applications to market promoters [3].”
Background
Brain Amyloid in Sporadic Young Onset Alzheimer’s Disease
Panegyres, P. K., & Robins, P. D. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220110 · Cited by 3
“Age-related amyloid accumulation presents a challenge to the diagnostic specificity of fluid or imaging biomarker evidence of amyloidosis beyond the 7th decade [4], which, in turn, casts uncertainty on its role in the pathogenesis of AD in these age ranges.”
Background
Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer’s Disease Trials
Ritchie, M., Witbracht, M. G., Nuño, M. M., Hoang, D. K., Gillen, D. L., & Grill, J. D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220801 · Cited by 3
“In additiontopeerreviewedpublications[6–9],thedeci-sion and in particular the associated controversies resulted in substantial coverage by lay media (e.g., [10–12]).”
Recent developments in geriatric psychopharmacology
Aftab, A., Lam, J. A., Liu, F., Ghosh, A., & Sajatovic, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1882848 · Cited by 3
“EMERGE and ENGAGE, in individuals with early AD [5,6].”
BackgroundMethod
Effect of Multiple Medicines on Dementia Initial Treatment: Experience and Thinking
Gan, J., Wang, M., Liu, S., Chen, Z., Wang, X.-D., & Ji, Y. (2021) · American Journal of Alzheimers Disease & Other Dementias · doi:10.1177/15333175211053134 · Cited by 2
“Aducanumab is recently approved by the US Food and Drug Administration (FDA) for the treatment of AD, with once-amonth intravenous injection.(34) Several studies have shown that the combination was significantly better than either Figure 1.”
Background
Anti-dementia medications: Fighting a losing battle?
Micov, A. M., & Pecikoza, U. B. (2020) · Arhiv za farmaciju · doi:10.5937/arhfarm2002055m · Cited by 3

Authors: Schneider, L.
Corresponding author: Schneider, Lon
ORCID: Schneider, Lon
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2020-02
Volume: 19
Issue: 2
Pages: 111-112
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(19)30480-6
OpenAlex: W2992893037
Cited by: 286
References: 0
Citations by year: 2026: 5 · 2025: 18 · 2024: 27 · 2023: 45 · 2022: 55 · 2021: 76 · 2020: 59
FWCI: 32.86
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: aducanumab, Alzheimer's disease, anti-amyloid antibodies, Biogen, data reanalysis, anti-amyloid therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A resurrection of aducanumab for Alzheimer's disease

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cited by

Metadata

Record

About these checks